BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24987915)

  • 21. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    Chudecka-Głaz A; Cymbaluk-Płoska A; Wężowska M; Menkiszak J
    PLoS One; 2018; 13(3):e0194270. PubMed ID: 29584739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic performance of HE4 and ROMA among Chinese women.
    Shen Y; Zhao L; Lu S
    Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4 and ROMA index in Czech postmenopausal women.
    Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
    Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.
    Pitynski K; Sporek A; Lipinska I; Banas T; Ludwin A; Bałajewicz-Nowak M
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):766-72. PubMed ID: 26701000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
    Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
    Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
    Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
    Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A
    Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA).
    Jeong TD; Cho EJ; Ko DH; Lee W; Chun S; Kwon HJ; Hong KS; Kim YM; Min WK
    Clin Chem Lab Med; 2017 Jul; 55(8):1209-1214. PubMed ID: 28107166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer.
    Kalapotharakos G; Asciutto C; Henic E; Casslén B; Borgfeldt C
    J Ovarian Res; 2012 Aug; 5(1):20. PubMed ID: 22909379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.
    Li PL; Zhang X; Li TF; Wang LL; Du LT; Yang YM; Li J; Wang HY; Zhang Y; Wang CX
    Clin Chim Acta; 2015 Jan; 439():148-53. PubMed ID: 25445414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.